|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NACA2 |
Gene summary for NACA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NACA2 | Gene ID | 342538 |
| Gene name | nascent polypeptide associated complex subunit alpha 2 | |
| Gene Alias | ANAC | |
| Cytomap | 17q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | Q9H009 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 342538 | NACA2 | C30 | Human | Oral cavity | OSCC | 3.15e-25 | 1.08e+00 | 0.3055 |
| 342538 | NACA2 | C38 | Human | Oral cavity | OSCC | 1.81e-13 | 1.03e+00 | 0.172 |
| 342538 | NACA2 | C43 | Human | Oral cavity | OSCC | 3.40e-29 | 4.81e-01 | 0.1704 |
| 342538 | NACA2 | C46 | Human | Oral cavity | OSCC | 1.06e-30 | 7.63e-01 | 0.1673 |
| 342538 | NACA2 | C57 | Human | Oral cavity | OSCC | 6.01e-03 | 2.66e-01 | 0.1679 |
| 342538 | NACA2 | C08 | Human | Oral cavity | OSCC | 6.79e-09 | 2.38e-01 | 0.1919 |
| 342538 | NACA2 | C09 | Human | Oral cavity | OSCC | 5.68e-09 | 3.87e-01 | 0.1431 |
| 342538 | NACA2 | LN46 | Human | Oral cavity | OSCC | 4.50e-10 | 4.96e-01 | 0.1666 |
| 342538 | NACA2 | LP15 | Human | Oral cavity | LP | 2.59e-06 | 1.03e+00 | 0.2174 |
| 342538 | NACA2 | LP17 | Human | Oral cavity | LP | 4.63e-07 | 8.35e-01 | 0.2349 |
| 342538 | NACA2 | P1_S1_AK | Human | Skin | AK | 1.59e-02 | -1.91e-01 | -0.3399 |
| 342538 | NACA2 | P2_S3_AK | Human | Skin | AK | 4.94e-03 | -2.02e-01 | -0.3287 |
| 342538 | NACA2 | P3_S6_AK | Human | Skin | AK | 3.07e-05 | -2.01e-01 | -0.3256 |
| 342538 | NACA2 | P5_S10_cSCC | Human | Skin | cSCC | 4.64e-07 | -2.08e-01 | -0.299 |
| 342538 | NACA2 | P1_cSCC | Human | Skin | cSCC | 2.76e-20 | 8.44e-01 | 0.0292 |
| 342538 | NACA2 | P10_cSCC | Human | Skin | cSCC | 5.46e-06 | 4.12e-01 | 0.1017 |
| 342538 | NACA2 | cSCC_p1 | Human | Skin | cSCC | 4.64e-07 | -2.06e-01 | -0.1916 |
| 342538 | NACA2 | cSCC_p10 | Human | Skin | cSCC | 9.96e-07 | -2.08e-01 | -0.2095 |
| 342538 | NACA2 | cSCC_p11 | Human | Skin | cSCC | 2.15e-08 | -2.04e-01 | -0.2102 |
| 342538 | NACA2 | cSCC_p3 | Human | Skin | cSCC | 9.96e-07 | -2.08e-01 | -0.2085 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:009015018 | Oral cavity | OSCC | establishment of protein localization to membrane | 163/7305 | 260/18723 | 7.13e-15 | 4.47e-13 | 163 |
| GO:00066123 | Oral cavity | OSCC | protein targeting to membrane | 75/7305 | 131/18723 | 1.72e-05 | 1.69e-04 | 75 |
| GO:0006605110 | Oral cavity | LP | protein targeting | 156/4623 | 314/18723 | 5.43e-22 | 1.62e-19 | 156 |
| GO:009015019 | Oral cavity | LP | establishment of protein localization to membrane | 128/4623 | 260/18723 | 7.19e-18 | 1.19e-15 | 128 |
| GO:000661211 | Oral cavity | LP | protein targeting to membrane | 60/4623 | 131/18723 | 1.10e-07 | 3.59e-06 | 60 |
| GO:000660526 | Skin | AK | protein targeting | 53/1910 | 314/18723 | 1.67e-04 | 1.94e-03 | 53 |
| GO:009015023 | Skin | AK | establishment of protein localization to membrane | 45/1910 | 260/18723 | 2.84e-04 | 2.99e-03 | 45 |
| GO:000660527 | Skin | cSCC | protein targeting | 153/4864 | 314/18723 | 2.62e-18 | 3.36e-16 | 153 |
| GO:009015024 | Skin | cSCC | establishment of protein localization to membrane | 123/4864 | 260/18723 | 8.34e-14 | 5.18e-12 | 123 |
| GO:00066125 | Skin | cSCC | protein targeting to membrane | 54/4864 | 131/18723 | 9.79e-05 | 9.11e-04 | 54 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NACA2 | SNV | Missense_Mutation | c.381N>T | p.Lys127Asn | p.K127N | Q9H009 | protein_coding | deleterious(0.01) | possibly_damaging(0.565) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NACA2 | SNV | Missense_Mutation | c.88N>A | p.Asp30Asn | p.D30N | Q9H009 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NACA2 | deletion | Frame_Shift_Del | novel | c.221delA | p.Lys74ArgfsTer48 | p.K74Rfs*48 | Q9H009 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| NACA2 | SNV | Missense_Mutation | rs764593531 | c.350N>T | p.Ser117Leu | p.S117L | Q9H009 | protein_coding | tolerated(0.06) | benign(0.036) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NACA2 | SNV | Missense_Mutation | c.211C>T | p.Arg71Trp | p.R71W | Q9H009 | protein_coding | tolerated(0.08) | benign(0.026) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| NACA2 | SNV | Missense_Mutation | novel | c.595N>A | p.Leu199Met | p.L199M | Q9H009 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NACA2 | SNV | Missense_Mutation | c.211C>T | p.Arg71Trp | p.R71W | Q9H009 | protein_coding | tolerated(0.08) | benign(0.026) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| NACA2 | SNV | Missense_Mutation | c.256N>A | p.Leu86Ile | p.L86I | Q9H009 | protein_coding | deleterious(0) | benign(0.15) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NACA2 | SNV | Missense_Mutation | rs781705734 | c.626C>T | p.Ala209Val | p.A209V | Q9H009 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NACA2 | SNV | Missense_Mutation | novel | c.50N>T | p.Pro17Leu | p.P17L | Q9H009 | protein_coding | tolerated(0.08) | benign(0) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |